Fathom Therapeutics has successfully secured $47 million in a Series A funding round to enhance its innovative drug discovery platform that leverages artificial intelligence and physics.
This financing round, led by Sutter Hill Ventures and supported by notable investors like Chemistry and Alexandria Venture Investments, aims to propel the development of Fathom's AI-powered platform, Microcosmos. This proprietary engine simulates protein dynamics at an atomic level, offering a more accurate depiction of how proteins function within living cells compared to traditional static models. The technology reportedly accelerates protein dynamics modeling by up to 10,000 times while maintaining precision.
Fathom's approach has already yielded promising results, including the rapid development of drug candidates targeting previously challenging protein targets. The company, founded by experts in computational biology and AI-driven drug discovery, plans to utilize the new funding to enhance its lab capabilities and expand its pipeline of high-impact therapies. Additionally, the company has announced key leadership appointments and the formation of a Scientific Advisory Board to strengthen its research efforts.
The investment reflects a growing interest in AI-enhanced drug discovery methods, particularly those that merge machine learning with advanced physics simulations to expedite and refine therapeutic development. As Fathom continues to push the boundaries of drug design, its efforts could lead to breakthroughs in creating treatments that were once deemed unattainable.